[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BridgeBio Pharma director and CEO Neil Kumar reported planned sales under a Rule 10b5-1 plan adopted March 31, 2025. The Form 4 discloses multiple dispositions on September 4–5, 2025 totaling 223,090 shares sold of BridgeBio common stock at weighted-average prices in several ranges between about $50.52 and $53.91 per share. Following the reported transactions, the filing shows Kumar's indirect beneficial holdings via two trusts of 4,678,447 shares and 875,686 shares, respectively. The report was signed by an attorney-in-fact and states the reporting person disclaims beneficial ownership except for any pecuniary interest.

Positive

• Sales executed under a Rule 10b5-1 plan, indicating pre-planned transactions and affirmative defense intent
• Complete Form 4 disclosure with weighted-average price ranges and post-transaction beneficial ownership shown
• Reporting person retains substantial indirect holdings via two trusts after the sales

Negative

• Material insider dispositions totaling 223,090 shares were sold over two days, which reduces insider-held shares
• Sales occurred across multiple price ranges, indicating staggered disposals rather than a single clean price

Insights

Financial Analyst

TL;DR: Insider sales of 223,090 shares were executed under an established 10b5-1 plan; disclosure is complete and shows indirect holdings via trusts.

The Form 4 documents systematic dispositions on September 4–5, 2025, under a Rule 10b5-1 plan adopted March 31, 2025. Sales occurred across several price bands producing weighted-average prices reported in the footnotes. The filing quantifies post-transaction indirect beneficial ownership via two trusts and includes the required disclaimer of beneficial ownership except for any pecuniary interest. For investors, this is a routine, pre-planned insider sale with full Form 4 disclosure.

Corporate Governance Expert

TL;DR: CEO/director used a documented 10b5-1 plan and properly reported multiple disposals; ownership remains substantial through trusts.

The disclosure indicates adherence to a written 10b5-1 sales plan and timely Section 16 reporting. The reporting person is identified as both CEO and director and reports indirect ownership through two trusts where he is a co-trustee. The filing includes customary disclaimers and weighted-average price footnotes detailing price ranges. Documentation appears to meet Form 4 requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2025		S(1)		14,525	D	$51.1504(2)	4,703,922	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	09/04/2025		S(1)		5,475	D	$51.8543(4)	4,698,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	09/05/2025		S(1)		2,300	D	$51.9546(5)	4,696,147	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	09/05/2025		S(1)		16,800	D	$53.1622(6)	4,679,347	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	09/05/2025		S(1)		900	D	$53.8044(7)	4,678,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	09/04/2025		S(1)		14,558	D	$51.1567(8)	901,128	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	09/04/2025		S(1)		5,442	D	$51.8535(9)	895,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	09/05/2025		S(1)		2,300	D	$51.9625(10)	893,386	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	09/05/2025		S(1)		16,900	D	$53.1627(6)	876,486	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	09/05/2025		S(1)		800	D	$53.7994(11)	875,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock								223,090	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $50.53 to $51.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. Represents the weighted average sale price of the shares sold from $51.53 to $52.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. Represents the weighted average sale price of the shares sold from $51.58 to $52.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

6. Represents the weighted average sale price of the shares sold from $52.65 to $53.62 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

7. Represents the weighted average sale price of the shares sold from $53.70 to $53.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

8. Represents the weighted average sale price of the shares sold from $50.52 to $51.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

9. Represents the weighted average sale price of the shares sold from $51.52 to $52.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

10. Represents the weighted average sale price of the shares sold from $51.64 to $52.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

11. Represents the weighted average sale price of the shares sold from $53.66 to $53.91 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BridgeBio (BBIO) insider Neil Kumar report on this Form 4?

He reported planned sales of 223,090 shares executed September 4–5, 2025 under a 10b5-1 sales plan adopted March 31, 2025.

How many shares were sold and at what prices?

223,090 shares were sold at weighted-average prices reported in ranges between approximately $50.52 and $53.91 per share.

What ownership remains after the reported transactions?

Indirect beneficial ownership is reported as 4,678,447 shares and 875,686 shares held via two trusts of which Kumar is a co-trustee.

Were the sales part of a planned trading program?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025.

Who signed the Form 4?

The signature was executed by Will Solis, Attorney-in-Fact on behalf of the reporting person on 09/08/2025.